Recently it has been proposed that di-methylation of histone H3 on lysine 4 (H3K4me2) acts as an epigenetic memory to maintain transcriptional patterns in developing tissues. This model suggests that there may be a requirement to reprogram this modification in the germline to prevent transcriptional memory from being inappropriately transmitted to the next generation. We asked if SPR-5, the C. elegans ortholog of the H3K4me2 demethylase LSD1/KDM1, plays a role in epigenetically reprogramming H3K4me2. We show that spr-5 mutants exhibit progressive sterility over many generations due to defects in oogenesis and spermatogenesis. These defects correlate with a progressive failure to erase H3K4me2 in the primordial germ cells, resulting in the misregulation of spermatogenesis-expressed genes due to the transgenerational accumulation of H3K4me2 at these loci. These results suggest that H3K4me2 can serve as an epigenetic memory and that LSD1/KDM1 demethylases play a critical role in the reprogramming of this memory in the germline, preventing inappropriate epigenetic information from being propagated from one generation to the next.

Lysine-specific demethylase 1 (KDM1A) is a transcriptional coregulator that can function in both the activation and repression of gene expression, depending upon context. KDM1A plays an important role in hematopoiesis and was identified as a dependency factor in leukemia stem cell populations. Therefore, we investigated the consequences of inhibiting KDM1A in a panel of cell lines representing all acute myelogenous leukemia (AML) subtypes using selective, reversible and irreversible KDM1A smallmolecule inhibitors. Cell models of AML, CML, and T-ALL were potently affected by KDM1A inhibition, and cells bearing RUNX1-RUNX1T1 (AML1-ETO) translocations were especially among the most sensitive. RNAi-mediated silencing of KDM1A also effectively suppressed growth of RUNX1-RUNX1T1-containing cell lines. Furthermore, pharmacologic inhibition of KDM1A resulted in complete abrogation of tumor growth in an AML xenograft model harboring RUNX1-RUNX1T1 translocations. We unexpectedly found that KDM1A-targeting compounds not only inhibited the catalytic activity of the enzyme, but evicted KDM1A from target genes. Accordingly, compound-mediated KDM1A eviction was associated with elevated levels of local histone H3 lysine 4 dimethylation, and increased target gene expression, which was further accompanied by cellular differentiation and induction of cell death. Finally, our finding that KDM1A inhibitors effectively synergize with multiple conventional as well as candidate anti-AML agents affords a framework for potential future clinical application. Cancer Res; 76(7); 1975-88. Ó2016 AACR.

No abstract

No abstract

No abstract